Direct-to-digital histopathology

Minimize histology workflows, Maximize pathology data.

The combination of key scientific advancements, clearing histology and multiphoton microscopy, provides in-depth, high-quality histopathology data in hours without the need for manual processes. 

 

About Applikate

Applikate Technologies is a hardware and software company that has developed the first automated histology platform with integrated digital imaging. Our patented technology stains and images whole samples without the need for physical slicing. The platform automates the pathology workflow, cuts processing time, lowers labor and materials costs, improves image quality, and reduces the risk of misdiagnosis.

Our Mission

Applikate's mission is to modernize pathology with technology that significantly reduces hospital costs, improves medical diagnosis, and enables a faster clinical response to patients.

Our Vision

Applikate envisions a world without the need for physical slides and prohibitively expensive histology equipment and storage.

Our Mission

Applikate's mission is to modernize pathology with technology that significantly reduces hospital costs, improves medical diagnosis, and enables a faster clinical response to patients.

Our Vision

Applikate envisions a world without the need for physical slides and prohibitively expensive histology equipment and storage.

The Applikate Advantage

From over 20 manual steps reduced to 3 simple steps.

The time and cost of producing physical slides constrains the number of slides per patient that a pathologist reviews, limiting the diagnostic information at their disposal.

Immediate visualization of multiple tissue layers

Globally accessible images from software that navigates multiple tissue levels for improved diagnosis and analysis.

Elimination of physical slides

Legacy technologies compensate for physical slide limitations by layering more equipment and steps on an archaic process.

High resolution multiphoton microscopy at depth

The fastest high-resolution multiphoton microscope in the world, sub-micron resolution at depth.

Important Milestones

Since 2013, Applikate has been revolutionizing pathology, reducing medical errors, and lowering cost.

2013

Applikate Founded

Richard Torres, MD, MS and Michael Levene, PhD co-found Applikate Technologies, LLC in New Haven, CT after publishing an innovative approach using unique chemical combinations and advanced microscopy.

2014

First Grant

National Cancer Institute awards Applikate’s first NIH SBIR grant.

2016

Article Publication

Published article illustrates unique capabilities of CHiMP for assessment of human renal tissue specimens.

2017

Follow-On Grant

Applikate receives follow-on NIH/NCI SBIR grant funding to continue CHiMP development.

2018

First Clinical Study

Applikate Technologies and Yale-New Haven Hospital begin first clinical study using Applikate’s CHiMP platform for prostate cancer patients.

2019

Fourth NIH Award

Applikate awarded fourth NIH/NCI SBIR to explore specialized applications of CHiMP.

2019

NIDDK Grant

Applikate receives grant from National Institute of Diabetes and Digestive and Kidney Diseases for development focused on renal pathology.

2020

Key Patents Granted

U.S. Patent Office grants key patents to Applikate covering various aspects of the CHiMP platform.

2020

Applikate Joins CDL

Applikate joins the Creative Destruction Lab (CDL) business incubator.

2020

Prostate Cancer Diagnosis Study

Published prostate cancer diagnostics study demonstrates viability of CHiMP as a primary diagnostic platform with critical advantages.

2021

CDL Showcase

CDL showcases Applikate at its annual Super Session.

2021

Over-Subscribed Seed Round

Applikate closes over-subscribed seed round and becomes Applikate Technologies, Inc.

2022

Second Clinical Validation Round

Applikate begins second phase of clinical validation studies using CHiMP.

Subscribe for exclusive updates

Applikate Technologies provides an elegant solution to the difficult and time-consuming problems faced by pathologists and their staff. The company’s solution offers a revolutionary approach to histology without requiring new skills, extensive training, or prohibitive costs. This technology has not yet been cleared by FDA for diagnostic use and is currently for Research Use Only.

Scroll to Top

 

Ted Klekman

SVP, Sales and Marketing

Ted Klekman leads sales and commercialization efforts at Applikate. He leverages 30 years of experience in healthcare software sales and relationship management to expand adoption in preclinical and clinical markets. 

As a graduate in Health Care Administration from California State University, Ted began his sales career at Softmed Systems, Inc. where he developed at VP of Sales over 14 years. He then drove sales at Landon IP, CPA Global and as Chief Sales Officer at Ensemble IP.   

Icon-linkedin-1
 

Kelsey Moore, PhD

Director of Market Development

Kelsey Moore leads market development and communications at Applikate. She is a cardiovascular researcher and life science marketer with 10 years of experience in preclinical research and histology techniques. 

Through her PhD, she identified molecular and genetic mechanisms of valve disease and managed model development, tissue and cell processing methods, and high-resolution immunofluorescence imaging. This research led to 14 first and co-author manuscripts and an F31 Predoctoral Fellowship awarded by the NIH/NHLBI. 

Since 2021, Kelsey has consulted with biopharmaceutical researchers as a sales and marketing professional. 

Icon-linkedin-1 Book
 
Johns Hopkins University
MD, PhD
 
Harvard University
Bachelor’s Degree

John Sinard, MD, PhD

Advisor

John Sinard is an Advisor to Applikate as a board-certified anatomic pathologist and Pathology Informatics expert. He is the Vice Chair of Pathology at Yale University and has developed software for over 30 years. 

John earned his MD and PhD from Johns Hopkins and completed his residency training and fellowship at Yale-New Haven Hospital. Active in autopsy, surgical pathology, opthalmic and pulmonary pathology, he has co-authored 96 publications. 

Motivated to deliver modern data management tools and digital pathology to practicing physicians, John founded the Pathology Informatics Program at Yale. 

Icon-Profile Icon-linkedin-1
 
 
Machine Learning

William Tunstall-Pedoe

Investor, Technology Expert, and Entrepreneur
William Tunstall-Pedoe is an entrepreneur who founded the British voice-assistant company Evi, which was purchased by Amazon in 2012 and became the basis for Amazon Alex and Echo devices. William mentors and invests in innovative startups and has holdings in more than 70 companies.
Icon-linkedin-1 Icon-monitor
 
 

John Turner

Medical Expert, Pathologist, and Business Advisor
John Turner trained as resident and fellow at Duke University University Medical Center receiving his boards in Anatomic, Clinical, and Dermatopathology. A practicing pathologist, he is the HCA/ForwardPathology Solutions Capital Division Medical Director and Chief of the Medical Staff for CJW Medical Center. Dr. Turner is a medical advisor to Applikate.
Icon-linkedin-1 Icon-monitor
 

Andrew Nutter

Investor, Technology Expert, and Entrepreneur
Andrew is the co-founder of Gama, a deep space exploration company. He is an investor in over 60 companies across a range of industries, from synthetic biology to nuclear fusion. Previously, Andrew built Westwing, a publicly listed home and living ecommerce business across Europe, Russia, and Brazil. He is a veteran of Balderton Capital and McKinsey & Company.
Icon-linkedin-1 Icon-twitter-1

 
 

Dick Hamrick, MD, MBA

Board Member, Advisor

Dick Hamrick serves as a Board Member and Advisor to Applikate. He is a pulmonary/critical care physician, investor, business advisor, and healthcare administration expert with over 30 years of diverse experience.

Following medical school at VCU, Dr. Hamrick completed his residency at West Virginia University Medical Center, and a fellowship in pulmonary diseases from Georgetown University Medical Center. He then practiced pulmonary medicine in Richmond for 22 year and later, pursued an MBA at VCU. Serving as the Chief Medical Officer for Hospital Corporation of American (HCA) Healthcare’s Capital Divison, he helped manage a network of 18 hospitals and associated operational components. 

Since retiring in 2019, Dr. Hamrick has become a policy leader and healthcare consultant to a plethora of healthcare systems and early-stage companies as Principal of Hamrick & Company throughout Virginia and beyond.

Icon-linkedin-1 Icon-Profile

Ron Bridges

Investor, Physician, Medical Expert, and Professor
Ron Bridges is a Professor of Medicine and Gastroenterologist at the Cumming School of Medicine, University of Calgary. He has held several senior leadership roles, authored more than 40 papers and is actively involved as a mentor at the Creative Destruction Lab. Ron is an angel investor with an interest in medical devices and health care innovations.
Icon-linkedin-1 Icon-bookmark

Donald Plewes

Investor, Professor, and Medical Device Expert
Donald Plewes is Professor Emeritus from the Department of Medical Biophysics of the University of Toronto. His career has been devoted to research in the physics of medical imaging and has included x-ray imaging, computed tomography, ultrasound, and magnetic resonance imaging with clinical applications. His research proceeds from bench science and clinical trials; and has led to the successful commercialization of advanced technologies for breast screening and magnetic resonance imaging.

Dr. Plewes has published widely, holds numerous patents, and is an investor in and expert advisor to Applikate Technologies.
MSc, Aviation Systems
 
 
 

Chris Hadfield

Investor, Astronaut, and Technology Expert
Chris Hadfield is an engineer, military fighter/test pilot and thrice-flown astronaut, having done two spacewalks and commanded the International Space Station. He is an advisor/director for multiple high-tech companies, and leads the Space stream at the Creative Destruction Lab tech incubator. Chris is a four-time internationally best-selling author, a professor at U Waterloo and online at Masterclass, and has created/hosted TV series with both BBC and National Geographic. Chris is an investor in Applikate Technologies and serves as an advisor to the company.
Icon-linkedin-1 Icon-twitter-1 Icon-monitor

Cohort 4 Full Time, Certificate 2019

 

 

 

David Hunt, MBA

Board Chair
Dave Hunt leads the business functions of Applikate and chairs the Board of Directors. He is also the CEO and majority shareholder at Ensemble IP. 


Previously, he owned and led Landon IP, a large professional patent search and analytics company with operating offices in the United States, Japan, United Kingdom, Germany, India, and China. He is an early-stage investor in several medical device and AI-focused companies and led the Seed Series round for Applikate Technologies.
Dave is a graduate of the College of William & Mary (B.A., ‘87, M.B.A, ‘93) and the Harvard Business Analytics Program (’19) and is bilingual in English and Japanese.
Icon-linkedin-1 Icon-monitor
 

Michael Levene, Ph.D.

Co-Founder, COO, President
Michael Levene pioneered the combination of multiphoton microscopy with optical clearing of tissue and its application to pathology. He served on the faculty of Yale University from 2004 to 2014, after which he co-founded Applikate. Michael holds 20 granted U.S. Patents, authored 32 publications, and has raised more than $6.3 million in research support between 2007.
Prior to joining Yale,  Michael was a Research Associate in Applied and Engineering Physics at Cornell University, where he worked with Prof. Watt Webb and co-invented zero-mode waveguides for single molecule DNA sequencing, the technological foundation of Pacific Biosciences, Inc.
Icon-linkedin-1 Book
Yale University School of Medicine
 
 

Richard Torres, M.D.

Co-Founder, CEO
Rick Torres is a pathologist and biomedical engineer with expertise in medical laboratory instrumentation. He is board certified in Clinical and Anatomic Pathology and has worked as an independent consultant on commercial medical diagnostic devices. His clinical interests include flow cytometry, pathology informatics, and next generation sequencing for hematologic malignancies, having served as medical director of clinical chemistry, hematology, immunology, and flow cytometry laboratories.
Rick Torres co-invented the novel histology techniques and devices developed by Applikate, served on the faculty of Yale University, co-founded the company, serves as CEO, and holds several seminal patents. He maintains an adjunct appointment at Yale where he continues to perform part-time clinical interpretative work.
Icon-linkedin-1 Book Icon-monitor